Research, regulatory, and clinical decision-making: the importance of scientific integrity

Journal of Clinical Epidemiology

Volumn 93, Issue , 2018, Pages 88-93

  Wallach, Joshua D ^a,b   Gonsalves, Gregg S ^a   Ross, Joseph S ^a,b,c  

^a YALE UNIVERSITY   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Data sharing; Integrity; Misconduct; Reproducibility; Transparency

Indexed keywords

CLINICAL DECISION MAKING; HUMAN; MEDICAL RESEARCH; METHODOLOGY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCIENTIFIC MISCONDUCT; RESEARCH ETHICS;

CLINICAL DECISION-MAKING; ETHICS, RESEARCH; HUMANS; SCIENTIFIC MISCONDUCT;

EID: 85032831042     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2017.08.021     Document Type: Note

References (37)

1. Baker, M., 1,500 scientists lift the lid on reproducibility. Nature 533 (2016), 452–454.
2. National Institutes of Health Office of Extramural Research. Research integrity: What is research integrity?. 2013 Available at https://grants.nih.gov/research_integrity/whatis.htm. (Accessed 5 October 2017)
3. Fanelli, D., How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS One, 4, 2009, e5738.
4. NIH. Conflict of Interest in Medical Research, Education, and Practice. 2009, National Academies Press (US), Washington, DC.
5. Ioannidis, J.P., Why most published research findings are false. PLoS Med, 2, 2005, e124.
6. Johansen, H.K., Gotzsche, P.C., Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 282 (1999), 1752–1759.
7. Hudson, K.L., Lauer, M.S., Collins, F.S., Toward a new era of trust and transparency in clinical trials. JAMA 316 (2016), 1353–1354.
8. Wallach, J.D., Sullivan, P.G., Trepanowski, J.F., Sainani, K.L., Steyerberg, E.W., Ioannidis, J.P., Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials. JAMA Intern Med 177 (2017), 554–560.
9. Dwan, K., Gamble, C., Williamson, P.R., Kirkham, J.J., Group, R.B., Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. PLoS One, 8, 2013, e66844.
10. New Drugs. Grounds for refusing application; Approval of application; “Substantial evidence” defined, 21 USC §355D. 2010 Available at http//www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapV-partA-sec355.htm. (Accessed 5 October 2017)
11. Downing, N.S., Aminawung, J.A., Shah, N.D., Krumholz, H.M., Ross, J.S., Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 311 (2014), 368–377.
12. Ciani, O., Buyse, M., Drummond, M., Rasi, G., Saad, E.D., Taylor, R.S., Time to review the role of surrogate end points in health policy: State of the Art and the way forward. Value Health 20 (2017), 487–495.
13. Fain, K., Daubresse, M., Alexander, G.C., The Food and Drug Administration Amendments Act and postmarketing commitments. JAMA 310 (2013), 202–204.
14. Pease, A.M., Krumholz, H.M., Downing, N.S., Aminawung, J.A., Shah, N.D., Ross, J.S., Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ, 357, 2017, j1680.
15. Downing, N.S., Shah, N.D., Aminawung, J.A., Pease, A.M., Zeitoun, J.D., Krumholz, H.M., et al. Postmarket safety events among novel therapeutics approved by the US Food and drug Administration between 2001 and 2010. JAMA 317 (2017), 1854–1863.
16. Dhruva, S., Desai, N., Karaca-Mandic, P., Shah, N., Ross, J., Medicare formulary changes after the 2013 American College of Cardiology/American Heart association Cholesterol guideline. J Am Coll Cardiol 69 (2017), 244–246.
17. Dhruva, S.S., Karaca-Mandic, P., Shah, N.D., Shaw, D.L., Ross, J.S., Associations between FDA black box warnings and Medicare formulary coverage Changes. Am J Manag Care 23 (2017), e310–e315.
18. Timmermans, S., Mauck, A., The promises and pitfalls of evidence-based medicine. Health Aff (Millwood) 24 (2005), 18–28.
19. Cabana, M.D., Rand, C.S., Powe, N.R., Wu, A.W., Wilson, M.H., Abboud, P.A., et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282 (1999), 1458–1465.
20. Desai, N.R., Bradley, S.M., Parzynski, C.S., Nallamothu, B.K., Chan, P.S., Spertus, J.A., et al. Appropriate Use Criteria for Coronary Revascularization and trends in Utilization, patient selection, and appropriateness of Percutaneous coronary intervention. JAMA 314 (2015), 2045–2053.
21. Layton, J.B., Kim, Y., Alexander, G.C., Emery, S.L., Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. JAMA 317 (2017), 1159–1166.
22. Greenway, T., Ross, J.S., US drug marketing: how does promotion correspond with health value?. BMJ, 357, 2017, j1855.
23. Ioannidis, J.P., How to make more published research true. PLoS Med, 11, 2014, e1001747.
24. Zarin, D.A., Tse, T., Ide, N.C., Trial registration at ClinicalTrials.gov between May and October 2005. N Engl J Med 353 (2005), 2779–2787.
25. The Food and Drug Administration Amendments Act of 2007. In: Public Law 110-85. Available at https://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf.
26. Zarin, D.A., Tse, T., Williams, R.J., Califf, R.M., Ide, N.C., The ClinicalTrials.gov results database–update and key issues. N Engl J Med 364 (2011), 852–860.
27. Zarin, D.A., Tse, T., Sheehan, J., The proposed rule for U.S. clinical trial registration and results submission. N Engl J Med 372 (2015), 174–180.
28. Krumholz, H.M., Documenting the methods history: would it improve the interpretability of studies?. Circ Cardiovasc Qual Outcomes 5 (2012), 418–419.
29. Knottnerus, J.A., Tugwell, P., Evidence-based medicine: achievements and prospects. J Clin Epidemiol 84 (2017), 1–2.
30. Institute of Medicine (IOM). Sharing clinical trial data: maximizing benefits, minimizing risks. 2015, The National Academies Press, Washington, DC.
31. Taichman, D.B., Backus, J., Baethge, C., Bauchner, H., de Leeuw, P.W., Drazen, J.M., et al. Sharing clinical trial data–a proposal from the International Committee of medical journal editors. N Engl J Med 374 (2016), 384–386.
32. Sipp, D., McCabe, C., Rasko, J.E., Show drugs work before selling them. Nature 543 (2017), 174–175.
33. Fox, D.M., Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions. Health Aff (Millwood) 24 (2005), 114–122.
34. Taylor, R.S., Drummond, M.F., Salkeld, G., Sullivan, S.D., Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329 (2004), 972–975.
35. Rose, A.J., Fischer, S.H., Paasche-Orlow, M.K., Beyond medication Reconciliation: the correct medication list. JAMA 317 (2017), 2057–2058.
36. Rising, J., Moscovitch, B., The Food and Drug Administration's unique device identification system: better postmarket data on the safety and effectiveness of medical devices. JAMA Intern Med 174 (2014), 1719–1720.
37. Spatz, E.S., Krumholz, H.M., Moulton, B.W., The new era of informed consent: getting to a reasonable-patient standard through shared decision making. JAMA 315 (2016), 2063–2064.